ESTRO 2025 - Abstract Book

S1690

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

At our center, 46 patients (93.8%) underwent a second resection, most with negative margins, while 3 patients (6.1%) did not undergo further surgery. RT was administered to 43 patients (87.7%), predominantly as adjuvant external beam radiotherapy (EBRT) using 3D techniques. Nineteen patients (38.7%) received CHT, primarily neoadjuvant regimens with doxorubicin and ifosfamide. Disease recurrence occurred in 28 patients (57.1%), primarily locally. Surgery was the most common salvage therapy, including for those with multiple recurrences. Patients initially treated outside our center often underwent surgery and/or RT after recurrence. Disease site did not correlate with recurrence. Estimated disease-free survival (DFS) was 37.2 months. RT improved DFS by 20% (p=0.12), and patients who did not receive RT had significantly higher failure rates (p<0.031). Local control (LC) rates were calculated at 1, 2, and 5 years (78,9%, 58% and 43,3%). After local failure, 11 patients received RT, and 10 received CHT. Of the 14 patients who experienced two recurrences, most were treated locally, with five receiving RT. Seven patients experienced three recurrences, three had four recurrences, and one patient recurred five times.